Cromos Pharma charting new territories as it looks east to Uzbekistan Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute. Large, ethnically diverse population Uzbekistan with a population
Cromos CEO outlines advantages of Central and Eastern Europe for clinical trials Why should international sponsors look at Central and Eastern Europe (CEE) as locations for their clinical trials? Want to find out more about the advantages of locating your study in this region and partnering with an international CRO which has 16 years of experience across CEE? Cromos Pharma’s CEO Vlad Bogin, MD, FACP outlines some of the benefits in a recent interview
Key factors to consider for rare disease/orphan drug development Rare disease clinical trials pose challenges above and beyond those encountered in trials involving more common conditions including: very few patients being available for clinical trials, those who are available are often geographically dispersed, lack of knowledge and data about a particular rare disease, the amount and quality of data generated by small-scale trials and
